Aug 27, 2025
Harbour BioMed Reports 2025 Interim Results
Aug 24, 2025
Harbour BioMed Appoints Yajie Li as Chief Medical Officer
Jul 29, 2025
Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025
Jul 27, 2025
Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results
Jul 23, 2025
HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma
Apr 09, 2025
Harbour BioMed Appoints Youchen Chen as Chief Financial Officer
Mar 31, 2025
Harbour BioMed Reports Full Year 2024 Financial Results
Mar 21, 2025
Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies
Mar 12, 2025
Harbour BioMed Launches Élancé Therapeutics to Advance Next-Generation Obesity Therapies
Mar 10, 2025
Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer
Mar 10, 2025
Harbour BioMed Appoints Dr. Ian Y. Liu as Global Head of Legal
Feb 20, 2025
Harbour BioMed and Insilico Medicine Achieve Strategic Collaboration to Advance AI-Driven Antibody Discovery and Development
Feb 13, 2025
Harbour BioMed Announces Business Progress and Update
Jan 10, 2025
Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases
Nov 14, 2024
Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer
Oct 09, 2024
Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors
Sep 14, 2024
Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024
Aug 28, 2024
Harbour BioMed Announces 2024 Interim Results
Jul 25, 2024
Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024
Jul 18, 2024
Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results